Refractory Angina

Refractory angina is chronic chest pain caused by coronary ischemia that persists despite guideline-directed medical therapy and revascularization options, or when those options are unsuitable. It is associated with substantial impairment in physical function, mental well-being, employment, and healthcare use. Assessment requires confirmation of ischemic symptoms, evaluation of coronary anatomy and ventricular function, and careful exclusion of noncardiac causes and potentially treatable obstructive disease. Management is multidisciplinary and typically combines optimized pharmacotherapy, risk-factor control, rehabilitation, psychosocial support, and selected device-based or procedural approaches.

Care is shifting from a narrow focus on repeat revascularization toward structured, patient-centered management of symptoms and function. Contemporary pathways emphasize systematic reassessment of ischemia, microvascular and vasospastic mechanisms, medication tolerability, comorbidities, and quality of life. Greater use of multidisciplinary chronic coronary disease services, shared decision-making, cardiac rehabilitation, and remote follow-up can improve continuity while reducing avoidable hospital encounters. Evidence remains uneven across advanced therapies, making appropriate patient selection and outcomes tracking essential.

Artificial intelligence can support refractory-angina care by identifying high-risk patterns in electrocardiography, imaging, electronic records, and remote symptom data. Potential applications include triaging patients for ischemia evaluation, distinguishing recurring angina from alternative causes of chest discomfort, recognizing medication-related issues, and detecting deterioration between visits. These tools should augment-not replace-clinical judgment because training data may underrepresent women, minority populations, and patients with complex comorbidity. Clinical validation, transparent performance reporting, privacy safeguards, and prospective evidence of improved outcomes are required before routine deployment.

North America generally has broad access to advanced diagnostics, subspecialty cardiology, rehabilitation, and interventional expertise, but affordability and fragmentation can limit continuity. Europe benefits from established chronic coronary disease guidance and referral networks, while access to specialized therapies varies among health systems. Asia-Pacific combines sophisticated cardiac centers with major rural and urban disparities, particularly across large and diverse populations. Latin America faces differences in availability of diagnostics, medicines, and revascularization, alongside growing cardiovascular disease burdens. The Middle East is expanding specialist capacity but retains variation between countries and public-private sectors. Africa faces the greatest constraints in diagnostic infrastructure, specialist coverage, essential medicines, and long-term follow-up, underscoring the value of scalable primary and secondary care pathways.

Across ASEAN, refractory-angina management is shaped by rapid urbanization, uneven specialist distribution, and differing reimbursement systems, making referral coordination and affordable medicines important priorities. BRICS countries share large populations and varied health-system capacity, with opportunities to strengthen standardized diagnosis, rehabilitation, registries, and access outside major cities. The European Union benefits from cross-border clinical guidance and quality initiatives, although national reimbursement and service organization remain heterogeneous. G7 systems generally possess strong research and specialist capabilities but continue to address aging populations, multimorbidity, and equitable access. GCC countries have invested heavily in cardiac infrastructure, while workforce distribution and dependence on centralized services remain relevant considerations. NATO members span diverse health systems, so collaboration is most useful around preparedness, interoperability, clinical standards, and continuity of care rather than assuming uniform provision.

Australia and Canada have advanced cardiovascular services but must address geographic distance and Indigenous and rural access gaps. Brazil and Mexico face substantial regional variation in specialist care, diagnostics, medicines, and public-system capacity. China and India combine high-end urban cardiac centers with large populations requiring stronger primary-care referral and rural coverage. France, Germany, Italy, Spain, and the United Kingdom have established cardiology networks, but differ in waiting times, reimbursement, rehabilitation uptake, and organization of chronic-care services. Japan and South Korea offer strong specialist infrastructure and aging-population expertise, with continued emphasis on integrated long-term management. Russia faces geographic and service-access challenges alongside the need for consistent evidence-based chronic coronary care. In the United States, sophisticated diagnostics and specialist options coexist with insurance, affordability, and geographic disparities.

Industry and health-system leaders should create referral pathways that connect primary care, general cardiology, interventional teams, rehabilitation, pain expertise, and behavioral-health support. Standardized protocols should document symptom burden, functional status, ischemia evaluation, medication response, revascularization suitability, and patient preferences. Investment should prioritize access to essential therapies, clinician education, culturally appropriate rehabilitation, and remote follow-up for patients with travel barriers. Organizations evaluating digital or AI tools should require representative validation, human oversight, cybersecurity controls, and measurable improvements in diagnostic timeliness, quality of life, safety, or avoidable utilization. Registries and routine patient-reported outcomes can support responsible adoption while identifying inequities.

This executive summary should be interpreted as a qualitative synthesis of verified clinical and health-system evidence rather than a quantitative market assessment. The approach includes reviewing authoritative guidelines, peer-reviewed studies, systematic reviews, regulatory and public-health materials, and documented care pathways relevant to chronic refractory angina. Findings are organized by clinical transformation, artificial-intelligence applications, geography, economic and policy groupings, and individual countries. Conclusions are limited to evidence-supported themes; where evidence is heterogeneous or access differs materially, the text states that uncertainty or variation explicitly.

Refractory angina remains a high-burden condition requiring more than repeated procedural escalation. The strongest direction is coordinated, individualized care that confirms the mechanism of symptoms, optimizes proven therapies, addresses quality of life, and connects patients with rehabilitation and specialist options when appropriate. Regional and country-level disparities make access, referral design, and affordability central implementation issues. Artificial intelligence may improve triage and longitudinal monitoring, but only with rigorous validation and clinical governance. Leaders should measure success through symptom relief, functional capacity, safety, patient experience, and equitable access.